A 68-year-old man with COPD (FEV₁ 35% predicted) presents with a 3-day history of productive cough, fever (38.5°C), and dyspnea. He lives in a community setting and has not been hospitalized in the past year. On examination, he has crackles in the right lower lobe. Chest X-ray shows a right lower lobe consolidation. Blood culture and sputum culture are pending. He is haemodynamically stable with SpO₂ 92% on room air. Which of the following is the most appropriate empirical antibiotic regimen for this patient?

Explanation

## Community-Acquired Pneumonia (CAP) Classification and Empirical Therapy ### Patient Risk Stratification This patient has **CAP with risk factors for drug-resistant organisms**: - COPD with moderate-to-severe airflow obstruction (FEV₁ 35%) - Age ≥65 years - Comorbidity (COPD) - However, **no recent hospitalization, no recent antibiotics, and haemodynamically stable** — this is NOT HAP or severe CAP **Key Point:** The presence of COPD elevates the risk for *Streptococcus pneumoniae* (including penicillin-resistant strains) and *Haemophilus influenzae*, but does NOT automatically mandate anti-pseudomonal coverage. ### Empirical Regimen for CAP in COPD (Non-Severe, Outpatient-Eligible) **Ceftriaxone + azithromycin** covers: - **Ceftriaxone**: *S. pneumoniae* (including penicillin-resistant), *H. influenzae*, *Moraxella catarrhalis*, gram-negative enterobacteria - **Azithromycin**: Atypical organisms (*Mycoplasma*, *Chlamydia*, *Legionella*), and provides additional gram-positive coverage This is the **standard empirical choice** for CAP in patients with COPD who are haemodynamically stable and do not meet criteria for severe CAP [cite:Harrison 21e Ch 297]. ### When to Escalate to Anti-Pseudomonal Therapy **Piperacillin-tazobactam + fluoroquinolone** is reserved for: 1. **HAP** (hospitalization ≥48 hours before symptom onset) 2. **Severe CAP** (ICU admission, septic shock, respiratory failure) 3. **Structural lung disease** (bronchiectasis, cystic fibrosis) 4. **Recent broad-spectrum antibiotics** or immunosuppression This patient meets **none** of these criteria. **High-Yield:** CAP in COPD ≠ HAP. The presence of COPD alone does not mandate anti-pseudomonal coverage unless the patient is critically ill or has recent healthcare exposure. ### Why Monotherapy Fails **Cefazolin** is a first-generation cephalosporin with poor activity against *H. influenzae* and **no coverage of atypical organisms** — inadequate for CAP. **Amoxicillin-clavulanate** has limited activity against penicillin-resistant *S. pneumoniae* and does not cover atypical organisms — suboptimal for CAP with COPD. **Clinical Pearl:** Always pair a beta-lactam with a macrolide or fluoroquinolone in CAP to ensure atypical coverage, even in the elderly.